Replies to post #207110 on $Pistol Pete$, $Mick$ & Friends Stock Picks /news,

[S-BEES-BUMBLEBEE]

$BZTG @.008! Charts (w/Acc.) & Links~






HEFFX.Inc
3 Raffles Place #07-01
Bharat Building Singapore 048617
[e-mail]

BZTG has zero stock dilution, tight float and is 100% debt free with no convertible toxic debt limiting upside!



https://www.HEFFX.com/

https://www.livetradingnews.com/

https://www.livetradingnews.com/buzz-technologies-inc-bztg-fintech-services-148691.html#.XX4no2ZCTFI

https://www.otcmarkets.com/stock/BZTG/news

Buzz Technologies returns to OTCIQ Press Release | 07/25/2019

Buzz Technologies is pleased to have returned to the OTCIQ.

Over the few weeks we will be releasing a series of updates, financial reports and corporate actions. (..)

https://www.otcmarkets.com/stock/BZTG/news/Buzz-Technologies-returns-to-OTCIQ?id=235239

Buzz Technologies, Inc. — BZTG FinTech Services Press Release | 08/06/2019

(..) Blockchain

Our Blockchain software environment for digital assets offers one of the largest production blockchain platforms in the world, we are using brand new technology combined with decades of exchange experience to build a radically better financial system. (..)

https://www.otcmarkets.com/stock/BZTG/news/Buzz-Technologies-Inc--BZTG-FinTech-Services?id=236369

Description

HEFFX has become one of Asia's leading financial services companies with interests in Publishing, Private Equity, Capital Markets, Mining, Retail, Transport and Agriculture that span every continent of the world. Our clearing partners have unprecedented experience in Equities, Options, Forex and Commodities brokering, banking, physical metals dealing, floor brokering and trading.

https://www.otcmarkets.com/stock/BZTG/profile

S. Jack Heffernan Ph.D
CEO at HEFFX
S. Jack Heffernan Ph.D. Funds Manager at HEFFX holds a Ph.D. in Economics and brings with him over 25 years of trading experience in Asia and hands on experience in Venture Capital, he has been involved in several start ups that have seen market capitalization over $500m and 1 that reach a peak market cap of $15b. He has managed and overseen start ups in Mining, Shipping, Technology and Financial Services.

https://www.livetradingnews.com/buzz-technologies-inc-bztg-fintech-services-148691.html#.XX4pQ2ZCTFJ

Share Structure~
Market Cap
2,403,771
09/13/2019
Authorized Shares
400,000,000
07/23/2019
Outstanding Shares
300,471,362
07/23/2019

https://www.otcmarkets.com/stock/BZTG/security



https://www.HEFFX.com/

$$$BZTG/HEFFX$$$

[$Pistol Pete$]

$RBII Rising BioSciences DD Pack

https://docs.google.com/presentation/d/1icN6rtj6VeUof1no3wDifSNHPd3lvXmpPJZ_1wvKqhM/edit#slide=id.g60fc6a8f89_1_47

[$Pistol Pete$]

$RBII Cloudy Skies Will Dissipate ::Rising Biosciences Inc, (OTC:RBII)

https://wsnewspublisher.com/index.php/2019/09/19/cloudy-skies-will-dissipate-rising-biosciences-inc-otcrbii/

[$Pistol Pete$]

$DDOG Podcast: Datadog Jumps 39%, and Two More Numbers to Know

https://www.marketwatch.com/articles/datadog-jumped-39-on-first-trading-day-51568970109?mod=mw_quote_news

[$Pistol Pete$]

$PMCB
Shareholder Update on our clinical trial product and the manufacturing process:

We have a product that we’re completely satisfied with — meaning that the cells we have genetically engineered do exactly what they were designed to do and our encapsulation process is exactly how we want it to be.

? The viability of the cells from our Master Cell Bank is well within the normal range.

? Cells from our Master Cell Bank produce the amount of enzymatic activity we designed them to produce and that is necessary to convert the prodrug we currently use to treat pancreatic cancer from its inactive form to its cancer killing form.

We are satisfied with everything in the “design” of the manufacturing process. We’re now trying to mimic the manufacturing process in Austrianova’s facility in Singapore — which works perfectly every single time — to the upscaled GMP manufacturing process in Austrianova’s manufacturing facility in Thailand. And from recent reports from Austrianova, we are very encouraged.

? As reported to PharmaCyte today, we are in the final days of our first of two back-to-back, staggered manufacturing runs. And everything is going smoothly to this point.

? Also, as reported to PharmaCyte today, the second of the two manufacturing runs is scheduled to begin today. If the first run is successful from start to finish, and all things are mimicked from the first run in this upcoming second run, then we're confident that we'll see a successful second run and then move to release testing.

PharmaCyte will be releasing a recorded version of the today's Shareholder Update Conference Call next week for those who missed the call.

[mick]

The Wright Brothers Flyer... The Ford Model T... An Electric Bike?

The licensing deal is with a Canadian electric scooter company — admittedly a quiet way of entering the market.

This week, however, the company followed up that press release with even bigger news: It's just received its first production order.

The order is for $500,000 worth of "motor drivers" — electronic devices designed to optimize electric motor performance by managing the inflow of electricity between the power source and the motor itself.

The more important factor here, however, is the client.

As one of the biggest and oldest electric motor producers in Mexico, Potencia Industrial builds everything from wind and hydroelectric generators to 15,000-horsepower electric motors.

It also builds smaller mass-market products like kits for converting gas-driven vehicles into electric power.

It will implement the motor drivers to optimize its existing products, but given the history of collaboration between these two companies, additional integration of DPM into more Potencia products is almost certain to occur in short order.

The Future Has Never Been Clearer

[mick]

OTCQB: ACCA
Acacia Diversified Holdings, Inc.www.acaciadiversifiedholdings.com an emerging cannabis company, is announcing its receipt of its second food-grade manufactures permit in the company's mobile fleet. The first state to grant MariJ a CPDHE permit was Colorado. MariJ has now been granted a Consumer and Industry Services Permit in the state of Tennessee. Eufloria Medical of Tennessee, Inc. (Eufloria), www.eufloriamedical.com is a wholly-owned subsidiary of (ACCA) and will be growing unique strains of hemp for MariJ Pharmaceuticals, Inc. (MariJ) www.marijinc.com to process and manufacture. Eufloria is a vertically-integrated hemp operation in Tennessee.

The most recent press release had a great response on the market and affected the price per share increase which may potentially reach .08. The emphasis is on MariJ since this subsidiary has great growing plans.

[mick]

Arconic, Beyond Meat, Blackstone, Bloom Energy, Datadog, Delta, Netflix, Ping, Xilinx and many more. Full ticker list: AMCX, ARNC, BYND, BX, CRWD, DDOG, DAL, NVST, FAST, HPW, MPW, NFLX, NKE, PLNT, SNH, SHAK, SKX, TPR, AMTD, TOL, XLNX.

[mick]

10/16/2019 LVVV Coverage Initiated for LiveWire Ergogenics Inc. via NetworkNewsWire
10/16/2019 LVGI LVGI Files Annual Report, Organizational Updates and New Joint Venture Announcement

[mick]

$NBRI-Recent Trades - Last 10 of 13
Time ET Ex Price Change Volume
14:08:39 Q 0.0001 2,000,000
13:48:30 Q 0.0001 5,000,000
13:48:27 Q 0.0001 500,000
11:34:42 Q 0.0001 1,500,000
11:10:34 Q 0.0001 533,890
11:08:07 Q 0.0001 695,099
11:08:02 Q 0.00006 -0.00004 15,000
11:06:55 Q 0.0001 2,274,845
11:04:16 Q 0.0001 450,000
11:04:11 Q 0.0001 1,180,000

[$Pistol Pete$]

$BPMX BioPharmX Reports Fiscal Third Quarter 2020 Financial Results and Provides Corporate Update BPMX



Dec 10, 2019, 16:05 ET

SAN JOSE, Calif., Dec. 10, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the fiscal quarter ended October 31, 2019.

Corporate Update

In the third quarter, we retained Locust Walk Partners, LLC, a global life science transaction firm focused on biopharmaceutical and medical technology companies, to provide transaction advisory services. Strategic transactions that have been or are being considered include a license or sale of our late-stage topical minocycline product candidates, a sale of the company or a strategic business combination. In order to preserve cash, the company has taken additional steps to reduce operating costs.

"The process with Locust Walk is ongoing," said Dr. Tierney, BioPharmX CEO. "We are optimistic that we will be able to announce a strategic transaction before the end of our fiscal year."

Third Quarter Financial Results

For the third fiscal quarter ended October 31, 2019, total operating expenses were $2.1 million, compared with total operating expenses of $4.4 million in the prior fiscal year's third quarter.

Net loss for the fiscal quarter ended October 31, 2019 was $2.1 million, or $0.14 per share, compared with a net loss of $4.4 million, or $0.57 per share, during the prior fiscal year's third quarter.

Excluding stock-based compensation expense, non-GAAP net loss for the fiscal quarter ended October 31, 2019 was $1.9 million, or $0.13 per share. During the third quarter of the prior fiscal year, the comparable non-GAAP net loss was $3.7 million, or $0.49 per share.

Cash and cash equivalents were $1.4 million as of October 31, 2019.

About BioPharmX® Corporation

BioPharmX Corporation (NYSE American: BPMX) is a specialty pharmaceutical company focused on developing prescription products utilizing its proprietary HyantX Topical Delivery System for dermatology indications. To learn more about BioPharmX, visit www.BioPharmX.com.

About Locust Walk

Locust Walk Partners, LLC is a global life science transaction firm. Their integrated team-based approach across capabilities, geographies, and industry segments delivers the right products, the right partners, and the most attractive sources of capital to get the right deals done for biopharma and medtech companies.

Use of Non-GAAP Measures

BioPharmX Corporation has supplemented its financial information prepared in accordance with generally accepted accounting principles in the United States ("GAAP") with non-GAAP measures, including non-GAAP net loss and non-GAAP net loss per share, which do not include stock-based compensation expense and the impact of changes in fair value of warrant liability. The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with GAAP. Management uses the non-GAAP information internally to evaluate its ongoing business, operational performance and cash requirements and believes these non-GAAP measures are useful to investors as they provide the same basis for evaluating BioPharmX Corporation's performance as applied by management.

BioPharmX Corporation has provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure. These non-GAAP measures may be different from non-GAAP measures used by other companies, including peer companies, and therefore, comparability may be limited. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. BioPharmX Corporation believes that non-GAAP measures have limitations in that they do not reflect all of the amounts associated with its results of operations as determined in accordance with GAAP and that these measures should be considered in addition to, not as a substitute for or in isolation from, measures prepared in accordance with GAAP. BioPharmX Corporation encourages investors and others to review the company's financial information in its entirety and not rely on a single financial measure.

Stock-based compensation expense represents non-cash charges related to equity awards granted by BioPharmX Corporation. The change in fair value of warrant liability results from the periodic revaluing of the warrant liability. These amounts are excluded from the company's non-GAAP net loss and non-GAAP net loss per share because they are not reflective of ongoing operating results in the period incurred. Although these may be recurring charges to BioPharmX Corporation's operations, management believes the measurement of these amounts can vary considerably from period to period and depend substantially on factors that are not a direct consequence of operating performance that is within management's control. Thus, management believes that excluding these charges from non-GAAP net loss and non-GAAP net loss per share facilitates comparisons of BioPharmX Corporation's operational performance in different periods, as well as with similarly determined non-GAAP financial measures of comparable companies.

Forward-Looking Statements

The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions, and strategies, including, but not limited to the company's engagement with Locust Walk and whether any strategic transactions will be entered into or as to the terms or timing of any such strategic transactions, and level of operating expenditures. Additional risks are set forth in our filings with the Securities and Exchange Commission, including those described in the company's Quarterly Report on Form 10-Q for the quarter ended October 31, 2019. The forward-looking statements included in this press release are made only as of the date hereof, and the company undertakes no obligation to publicly update such statements.

BioPharmX and HyantX are registered trademarks of BioPharmX, Inc.

--TABLES TO FOLLOW --


BIOPHARMX CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except per share amounts; unaudited)
















Three Months Ended


Nine Months Ended





October 31,


October 31,





2019


2018


2019


2018












Revenues, net


$ -


$ 10


$ -


$ 52

Cost of goods sold

-


60


-


80

Gross margin


-


(50)


-


(28)












Operating expenses:









Research and development

740


2,228


4,314


7,285


Sales and marketing

139


550


572


1,717


General and administrative

1,241


1,624


3,534


4,252



Total operating expenses

2,120


4,402


8,420


13,254













Loss from operations

(2,120)


(4,452)


(8,420)


(13,282)

Change in fair value of warrant liability

-


42


11


(1)

Other income, net

7


20


29


83


Loss before provision for income taxes

(2,113)


(4,390)


(8,380)


(13,200)


Provision for income taxes

-


-


2


2

Net and comprehensive loss

$ (2,113)


$ (4,390)


$(8,382)


$(13,202)












Net loss per share









Basic and diluted

($0.14)


($0.57)


($0.69)


($1.76)

Shares used in computing net loss per share









Basic and diluted

14,672


7,654


12,146


7,502




BIOPHARMX CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, unaudited)












October 31,


January 31,





2019


2019

Assets







Current assets:






Cash and cash equivalents

$ 1,427


$ 3,069



Prepaid expenses and other

391


316




Total current assets

1,818


3,385









Property and equipment, net

186


148


Operating lease right-of-use asset, net

1,002


—


Other


121


121




Total assets

$ 3,127


$ 3,654








Liabilities and Stockholders' Equity





Current liabilities:






Accounts payable

$ 687


$ 1,363



Accrued expenses and other

863


934




Total current liabilities

1,550


2,297









Long-term liabilities

860


59




Total liabilities

2,410


2,356









Stockholders' equity

717


1,298




Total liabilities and stockholders' equity

$ 3,127


$ 3,654




BIOPHARMX CORPORATION

Reconciliation of GAAP Net Loss to Non-GAAP Net Loss

(in thousands, except per share amounts; unaudited)
















Three Months Ended


Nine Months Ended





October 31,


October 31,





2019


2018


2019


2018













GAAP net loss available to common stockholders

$ (2,113)


$ (4,390)


$(8,382)


$(13,202)














Change in fair value of warrant liability

—


(42)


(11)


1



Stock-based compensation expense:











- Research and development

30


166


218


525




- Sales and marketing

12


114


45


355




- General and administrative

187


438


334


877




Total stock-based compensation expense

229


718


597


1,757



Total reconciling items

229


676


586


1,758


Non-GAAP net loss available to common stockholders

$ (1,884)


$ (3,714)


$(7,796)


$(11,444)













GAAP net loss available to common stockholders

$ (0.14)


$ (0.57)


$ (0.69)


$ (1.76)



Reconciling items











- Change in fair value of warrant liability

—


—


—


—




- Stock-based compensation expense

0.01


0.08


0.05


0.23













Non-GAAP net loss per share: basic and diluted

$ (0.13)


$ (0.49)


$ (0.64)


$ (1.53)













Shares used in computing non-GAAP net loss per share










Basic and diluted

14,672


7,654


12,146


7,502

SOURCE BioPharmX Corporation


Related Links
http://www.biopharmx.com

Also from this source

BioPharmX Receives Notice of Compliance Deadline Extension from...

BioPharmX Reports Fiscal Second Quarter 2020 Financial Results...
Explore
More news releases in similar topics

Health Care & Hospitals
Biotechnology
Medical Pharmaceuticals
Pharmaceuticals
Earnings
You just read:

BioPharmX Reports Fiscal Third Quarter 2020 Financial Results and Provides Corporate Update
NEWS PROVIDED BY

BioPharmX Corporation
Dec 10, 2019, 16:05 ET

[$Pistol Pete$]

Happy Lunar New Year!!!! The year of the rat

[insymbols]

$RJDG 3 Months Chart

[$Pistol Pete$]

$BPMX merger news out

https://www.prnewswire.com/news-releases/biopharmx-and-timber-pharmaceuticals-announce-entry-into-merger-agreement-300994838.html

[$Pistol Pete$]

$BPMX TMB-001 (topical isotretinoin)
TMB-001 (topical isotretinoin) is being developed for the treatment of moderate to severe subtypes of CI. In a Phase 2a study, treatment with TMB-001 was shown to be well tolerated with no evidence of systemic absorption of isotretinoin. There was also a clear signal of efficacy in the study with patients showing a reduction in scaling after eight weeks. In 2018, the FDA awarded $1.5 million to support Phase 2a and Phase 2b clinical trials evaluating TMB-001 through its Orphan Products Grant program. Timber expects to enroll the first patient in a Phase 2b clinical trial in Q4 2019.

If you are interested in any of Timber’s ongoing clinical research programs, please contact [e-mail].

[mick]

[-chart]www.stockta.com/cgi-bin/candle.pl?cobrand=&symb=MSMY&size=analysis&support=0.00,16,0.00,2,0.00,2,0.00,12,0.00,44,0.00,2,0.00,2,0.00,2,0.00,4,0.01,2&trend=[/chart]

[mick]

HI THERE, FOR OUR VISITORS, MMM PERSONS
RE;
MMM PERSONS Market Maker Signals M-MARKET,M-MAKER,M-MANIPULATOR


Penny traders believe that Market Makers (MM)

will "signal" moves in advance buy using
small amounts of buys or sells as "signals".

The "signals" are such a small amount of shares
(worth no more than 5 or 10 dollars) that
no trader would have paid a commission that
costs more than the amount of shares bought.

The "signals" are from one MM to another.

100 - I need shares.

200 - I need shares badly, but do not take the stock down.

300 - Take the price down so I can load shares

400 - Keep trading it sideways.

500 - Gap the stock.

This gap can be either up or down,
depending on the direction of the 500 signal.
======================================================
505 - I am short on shares
600 - Means provide resistance
900 - Means let the stock float
911 - Pending News/Press Release On The Way
1000 - Don't let it run
2100 - Let it run

http://www.pennystockdream.com/Market-Maker-Signals

ADDING;
List Of Market Maker Signals
1. 100 - I need Shares.
2. 200 - I need Shares badly but do not take the stock down.
3. 300 - Take (or I am taking) the stock down at least 30% so I can load shares.
4. 400 - Keep trading it sideways.
5. 500 - Gap the stock. Gap can be up or down, depending on direction of 500 signal.

6. 505 - I am short on shares
7. 600 - Apply resistance at the ASK to keep the price from increasing.
8. 700 - Move the price up.
9. 777 - Also recognized as a signal to move the price up.
10. 800 - Prepare for an increase in trading volume.

11. 900 - Allow the stock to float and trade freely.
12. 911 - Pending News/Press Release On The Way
13. 1000 - Don't let it run
14. 2100 - Let it run

[insymbols]

$ZOM 3 Months Chart